Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 56 ()
DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patientsECCO '19
Year: 2019
Authors: Bram Verstockt
colonoscopy, Mucosal healing, Vedolizumab, Mucosal healing, Real world data, Mucosal healing
Files: 1
DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel diseaseECCO '19
Year: 2019
Authors: Bram Verstockt
Mucosal healing, Prognosis, Anti-TNF agents, Vedolizumab
Files: 1
DOP39: Safety of Combination Biologic and Anti-Rejection Therapy Post-Liver Transplantation in Patients with Inflammatory Bowel DiseaseECCO '19
Year: 2019
Authors: Saleh Al Draiweesh
Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Ustekinumab, Vedolizumab, Sclerosing Cholangitis, IBD-associated cancer, Clostridium difficile, Colorectal cancer, CMV, IBD and malignancy, Mortality, Real world data, Patient reported outcomes
Files: 1
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s diseaseECCO '19
Year: 2019
Authors: Antoine Meyer
Anti-TNF agents, Biosimilars, Real world data
Files: 1
DOP42: Dietary Therapies Induce Rapid Response and Remission in Active Paediatric Crohn’s DiseaseECCO '19
Year: 2019
Authors: Rotem Sigall Boneh
CRP and other serum biomarkers, Disease activity Indices, Dietary therapy, Exclusive enteral nutrition, Paediatric, Disease activity indices
Files: 1
DOP44: Efficacy and safety of tacrolimus in ulcerative colitisECCO '19
Year: 2019
Authors: Iago Rodriguez-Lago
Ulcerative colitis, Tacrolimus, Real world data
Files: 1
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s diseaseECCO '19
Year: 2019
Authors: Niels Vande Casteele
Anti TNF drug levels, Therapeutic drug monitoring, Anti-TNF agents, Infliximab, Pharmacokinetics
Files: 1
DOP46: Extended induction treatment with mirikizumab in patients with moderately-to-severely active ulcerative colitisECCO '19
Year: 2019
Authors: William J, Sandborn
Ulcerative colitis, Commercial
Files: 1
DOP47: Sustained remission in patients with moderate to severe ulcerative colitisECCO '19
Year: 2019
Authors: Laurent Peyrin-Biroulet
Ulcerative colitis, Mucosal healing, Ustekinumab, Patient reported outcomes, Disease activity indices, Mucosal healing
Files: 1
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn's disease patientsECCO '19
Year: 2019
Authors: Geert D'Haens
S1P agonist
Files: 1
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitisECCO '19
Year: 2019
Authors: Walter Reinisch
Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers
Files: 1
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencingECCO '19
Year: 2019
Authors: Eun Suk Jung
Anti-TNF agents, Infliximab, Pharmacogenetics
Files: 1
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasoundECCO '19
Year: 2019
Authors: Christian Maaser
Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Mucosal healing, Ultrasound, Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Real world data, Mucosal healing
Files: 1
DOP58: IDeaL – a multi-center prospective Infliximab Dose to Level pharmacokinetic study during induction in pediatric Crohn’s diseaseECCO '19
Year: 2019
Authors: Geraldine H, Huynh
Anti TNF drug levels, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Therapeutic drug monitoring, Infliximab, Pharmacokinetics, Paediatric, Investigator-led
Files: 1
Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 56 ()